Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study.
atopic dermatitis
house dust mite
sublingual immunotherapy
Journal
Postepy dermatologii i alergologii
ISSN: 1642-395X
Titre abrégé: Postepy Dermatol Alergol
Pays: Poland
ID NLM: 101168357
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
05
07
2019
accepted:
13
07
2019
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
ppublish
Résumé
Sublingual immunotherapy (SLIT) has been shown to be efficacious in patients with airway allergic diseases. However, less data have been demonstrated to show the efficacy of SLIT in patients with atopic dermatitis (AD). This study is to evaluate, in a randomized controlled study, the effect of SLIT with house dust mite (HDM) in patients with mild-moderate AD. AD patients aged 4 to 60 years with a Scoring Atopic Dermatitis (SCORAD) score of 7-40 and sensitization to HDM were enrolled in the study. SLIT or control treatment was given for 24 months. SCORAD, visual analog scale (VAS) score were recorded at 6, 12, 24 month, and rescue medications were required to be recorded in the diary card. A serum level of specific IgE was tested at 24-month treatment. Ninety-six patients were enrolled, and forty-eight were allocated to SLIT. Thirty-nine patients in the SLIT group and thirty-eight patients in the control group completed the study. The patients in the SLIT group had significantly decreased ΔSCORAD, VAS and rescue medication score from 12 months' treatment compared with the control group ( Two years' SLIT to HDM significantly improved the clinical symptoms and reduced drug use in patients with mild-moderate AD. SLIT may represent an additional therapeutic tool for the treatment of AD in properly selected patients.
Identifiants
pubmed: 34408569
doi: 10.5114/ada.2021.104281
pii: 43472
pmc: PMC8362773
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-74Informations de copyright
Copyright © 2021 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Allergy Clin Immunol. 2004 Jun;113(6):1025-34; quiz 1035
pubmed: 15208578
J Allergy Clin Immunol. 2007 Jul;120(1):164-70
pubmed: 17543376
Allergy. 2006 Feb;61(2):202-5
pubmed: 16409197
Curr Med Res Opin. 2007 Oct;23(10):2503-6
pubmed: 17784996
Laryngoscope. 2013 Jun;123(6):1334-40
pubmed: 23616386
Ann Allergy Asthma Immunol. 2014 Dec;113(6):671-673.e1
pubmed: 25304342
Br J Dermatol. 2010 May;162(5):964-73
pubmed: 20331459
J Allergy Clin Immunol. 2006 Jul;118(1):3-21; quiz 22-3
pubmed: 16815133
J Allergy Clin Immunol. 1999 Dec;104(6):1273-9
pubmed: 10589012
Ann Dermatol. 2017 Feb;29(1):1-5
pubmed: 28223739
Yonsei Med J. 2012 Jan;53(1):158-63
pubmed: 22187247
Rev Alerg Mex. 2005 Nov-Dec;52(6):231-6
pubmed: 16568708
Lancet. 2006 Aug 26;368(9537):733-43
pubmed: 16935684
Dermatology. 1993;186(1):23-31
pubmed: 8435513
J Allergy Clin Immunol. 2007 Apr;119(4):792-5
pubmed: 17418659
J Clin Aesthet Dermatol. 2010 Jan;3(1):22-31
pubmed: 20725535
J Allergy Clin Immunol. 2006 May;117(5):1021-35
pubmed: 16675328
J Allergy Clin Immunol. 2004 May;113(5):832-6
pubmed: 15131563
Curr Opin Allergy Clin Immunol. 2007 Dec;7(6):542-46
pubmed: 17989532
Pol Merkur Lekarski. 2006 Dec;21(126):558-65
pubmed: 17405298
J Allergy Clin Immunol. 2006 Jul;118(1):152-69
pubmed: 16815151
Allergol Int. 2012 Jun;61(2):231-43
pubmed: 22361514
Int J Dermatol. 2014 May;53(5):650-5
pubmed: 23968339
World Allergy Organ J. 2014 Mar 28;7(1):6
pubmed: 24679069